Genetic alterations in the ALK gene occur in approximately 3-5% of cases of non-squamous non-small cell lung cancer (NSCLC). These rearrangements are critical in determining how cancer cells respond to treatment with ALK inhibitors. However, over time, some patients may develop resistance, leading to disease progression. In such cases, performing genetic analysis is crucial to detect new mutations that could be driving resistance, enabling healthcare providers to select the most appropriate next-line therapy. We present the case of a 56-year-old patient with advanced NSCLC who had an exceptional progression-free survival of 71 months. This case highlights the potential benefits of using sequential ALK inhibitors in the treatment of advanced ALK-rearranged lung adenocarcinoma. This case emphasizes the importance of genetic testing and tailored treatment approaches and offers optimism for improved patient outcomes in individuals with ALK-positive lung adenocarcinoma.
